

Ardea Biosciences, Inc./DE  
Form 8-K  
March 18, 2008

**Table of Contents**

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
FORM 8-K  
CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934  
Date of Report (Date of earliest event reported): March 17, 2008  
Ardea Biosciences, Inc.  
(Exact name of registrant as specified in its charter)**

<b>Delaware</b>	<b>1-33734</b>	<b>94-3200380</b>
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

<b>4939 Directors Place San Diego, California</b>	<b>92121</b>
(Address of principal executive offices)	(Zip Code)
Registrant's telephone number, including area code: <b>(858) 652-6500</b>	
<b>2131 Palomar Airport Road, Suite 300 Carlsbad, California</b>	

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**TABLE OF CONTENTS**

Item 2.02. Results of Operations and Financial Condition

Item 7.01. Regulation FD Disclosure

Item 9.01. Financial Statements and Exhibits

SIGNATURE

EXHIBIT LIST

EXHIBIT 99.1

EXHIBIT 99.2

---

**Table of Contents**

**Item 2.02. Results of Operations and Financial Condition.**

In the presentation referenced in Item 7 below, the Company disclosed that it ended fiscal year 2007 with approximately \$66.2 million in cash. Additionally, the Company reported that it expects to use \$45 - \$50 million to fund its operations in fiscal year 2008.

The information contained in this Item shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or incorporated by reference in any filing under the Securities Act of 1933, as amended (the Securities Act), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

**Item 7.01. Regulation FD Disclosure**

The Company intends to present at conferences and conduct meetings with investors, stockholders and analysts on or after March 18, 2008. A copy of the presentation materials to be used at those conferences and meetings and from time to time thereafter is filed as Exhibit 99.1 hereto. The Company does not intend to file any update of these presentation materials. The fact that these presentation materials are being furnished should not be deemed an admission as to the materiality of any information contained in the materials.

The Company has recently received certain clinical data related to its products and has announced a conference call on March 18, 2008 to discuss such data with investors, stockholders and analysts. A copy of the related press release is filed as Exhibit 99.2 to this Form 8-K and is incorporated herein by reference in its entirety.

The information in this Item 7.01 and Exhibits 99.1 and 99.2 attached hereto shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits. The following material is filed as an exhibit to this Current Report on Form 8-K:

<b>Exhibit Number</b>	<b>Document Description</b>
99.1	Ardea Biosciences, Inc. investor presentation materials to be used at conferences and meetings with investors, stockholders and analysts beginning on or after March 18, 2008, and to be used from time to time thereafter.
99.2	Press Release, dated March 17, 2008.

---

**Table of Contents**

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**ARDEA BIOSCIENCES, INC.**

Date: March 17, 2008

/s/ Barry D. Quart  
Barry D. Quart, Pharm. D  
Chief Executive Officer

---

**Table of Contents**

**EXHIBIT LIST**

<b>Exhibit Number</b>	<b>Document Description</b>
99.1	Ardea Biosciences, Inc. investor presentation materials to be used at conferences and meetings with investors, stockholders and analysts beginning on or after March 18, 2008, and to be used from time to time thereafter.
99.2	Press Release, dated March 17, 2008.